Specialty Pharmacy

Protein that helps cancer cells avoid death offers promising target.

The FDA today approved sirolimus, the first drug to treat lymphangioleiomyomatosis, a rare lung disease.

Novel drug target found in cells directly responsible for cartilage damage in affected joints.

Treatment is the first concentrated mealtime insulin analog to be approved by the FDA.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses potential methods for keeping high cost drugs accessible.

Amgen has terminated its co-development and commercialization of brodalumab with AstraZeneca after observing suicidal ideation and behavior in clinical trial participants.

Genetic variant found to be associated with the likelihood of patient response to interferon-beta.

Smokers face high risk of disease recurrence after completing treatment.

Discovery may accelerate search for effective vaccine.

Electronic prescribing technology is permitting pharmacists to focus less on administrative tasks and more on providing direct patient care.

Investigational drug will move to phase 3 studies.

No significant differences in use found between opioid users and nonusers.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the partnership between the National Association for Specialty Pharmacy and Specialty Pharmacy Times.

Treatment prior to surgery leads to fewer side effects and better quality of life.

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

Persistent HIV reservoirs present ongoing treatment challenge.

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

Drug mitigates elevated cardiovascular risk in infected patients.

Genetic variant regulates response to leading multiple sclerosis therapy.

Clients will benefit from accurate circulation information thanks to membership in tracking organization.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Paul Sipes, vice president of Spud Software, discusses how specialty pharmacies can best utilize technology to their advantage.

Health-systems leaders fear that a scaled-back 340B Federal Drug Pricing Program would hurt the very patients it was designed to benefit.

Clinical guidelines and government agencies are increasingly encouraging clinicians to consider patients' treatment preferences when chronic disease is present.

Anti-PDL1 agent with standard chemotherapy combination will now move to multiple phase 3 studies.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.

Agreement ensures MHA members better access to Mediware's homecare software solutions.

The FDA today amended its breakthrough therapy designation for an experimental hepatitis C drug combination.